Additional Parkinson's and
Movement Disorder
Studies at Penn
There are additional Parkinson’s disease (PD)
and movement disorder studies ongoing at Pennsylvania Hospital.
Click on the study name below for more details
and contact information: Imaging PD Studies, Genetics/Biomarker Studies, Therapeutic Studies, and Huntington's Disease Studies.
Imaging PD Studies:
- INSPECT: Changes in SPECT scan results for PD patients on dopamine agonists vs. levodopa. Click on the study name for more information.
- AVID: The AVID study is for patients in the early stages of PD and patients with DLB. The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in a group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson’s disease and to differentiate them from Alzheimer’s disease (AD) and control subjects. For more information contact Iman Affan at (215) 829-3582.
Genetics/Biomarker Studies:
- PPMI - Parkinson's Progression Markers Initiative:
The Parkinson’s Progression Markers Initiative (PPMI) is an observational research study to identify biomarkers of Parkinson’s disease (PD) progression. A biomarker is a substance or characteristic in our bodies that is associated with the presence of disease, or that changes over time in a way that can be linked to the progression of disease. An observational study means that study participants will undergo numerous tests and assessments of bodily processes related to PD, but will not receive an experimental drug or treatment. This study will use a combination of imaging techniques, collection of blood, urine, and spinal fluid, and clinical tests. For more information contact Baochan Tran, (215) 829-7104. - Genetics: Develop a better understanding of the genetic basis for PD. Click on the study name for more information.
- Biomarkers of Parkinson's disease: Click on the study name for more information.
- NPF: The purpose of the Registry is to collect data on individuals with Parkinson’s disease to better understand the illness and ultimately improve the care and survival of those individuals with the disease. The Patient Registry was started in 2009 as a means to monitor important trends in the Parkinson’s population and to improve understanding, treatment, and survival. For more information contact James Minger at (215) 829-7725.
Therapeutic PD Studies:
- Rivastigmine for Mild Cognitive Impairment in Parkinson’s Disease
- ADAGIO: Rasagiline and the progression of PD. Click on the study name for more information.
- NET-PD: Creatine and the progression of PD. Click on the study name for more information.
- CEREGENE: PD gene therapy surgical trial. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
- CEREGENE EXTENSION TRIAL: Follow up of the post-surgical patients. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
- ACADIA: Safety and effectiveness of an experimental medicine in treatment of Parkinson’s Disease Patients with Drug-Induced Psychosis. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
- MSA-P: Safety and effectivenss of rasagiline in treatment of patients with Multiple System Atrophy. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
- VA DBS Study: Collaborative study with the VA on long-term outcomes after Deep Brain Stimulation (DBS) with the Medtronic device. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
- ADAGIO Follow-Up Study: Long-term effects of rasagiline in patients with Parkinson’s disease. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
- ANS/St. Jude DBS Follow-Up Study: Long-term outcomes after Deep Brain Stimulation with the ANS/St. Jude device. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
Huntington's Disease Studies:
- COHORT: Following Huntington's disease patients or patients with the gene for HD. Click on the study name for more information.
- 2CARE: Coenzyme Q10 in Huntington's disease. Click on the study name for more information.
- CREST-E: Safety and effectiveness of high dose creatine in treatment of Huntington’s Disease. For more information contact Heather Maccarone at (215) 829-7181 or Mary Lloyd at (215) 829-2365.
To learn more about these studies with contact information, please visit http://www.uphs.upenn.edu/neuro/research/trials/parkinsons/index.html.
